Human Applications
A game-changing future for medicine
Human Applications
GMT has developed several specific treatment regimens for the Corona Viruses, HIV/AIDS, Leishmaniasis, Dengue, Malaria, Zika Virus, and Necrotizing Fasciitis (“flesh-eating bacteria.”) (which is caused by Group A Streptococcus (GAS) bacteria). This is the same type of bacteria that causes strep throat which the PCI-1 also readily inactivates.
Also in development is a self-contained miniature Irradiator (PCI-2) for use in remote areas. This has piqued the interest of many in South America, the Caribbean Basin, and European countries and their Departments of Wilderness, Departments of Mining, and Departments of Defense. The costs to treat indigenous diseases around the world are exorbitant, and this technology will make a huge impact on human health and worldwide health care budgets.
GMT offers developing countries throughout the world the ability to decrease their current costs to treat a multitude of diseases like COVID19, HIV/AIDS, HEP-C, Ebola, and others that are catastrophic in nature by as much as 90%. These diseases are a constant strain on the government healthcare budgets of developing countries and GMT can save billions of dollars and hundreds of millions of lives.
Read More Here...
We also have the collaboration and participation of more than 500 medical professionals from the US, Canada, Colombia, Brazil, Chile, Russia, Germany, Denmark, Dominican Republic, Mexico, Spain, Switzerland, South Africa, Liberia, Guinea, China, and the resources of some of the best physicists and engineers from over twelve countries.
All these professionals are collaborating with us in our clinical trials and in the concurrent implementation of PCI in various countries for COVID19 and HIV/AIDS. GMT’s clinical trials will provide GMT with worldwide certification to deliver a safe, viable treatment modality for any pathogen, be it a virus, bacteria, fungus, or parasite. These scientists understand that the success of GMT will provide humanity with the hope of a treatment for any infectious disease.
